Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11573577 | 0.86 | BTN3A1 (0.37) | BTN3A1GGPS1ALOX15ALDH1A1 | |
| SCHEMBL16406011 | 0.80 | GGPS1 (0.57) | GGPS1ALOX15ALDH1A1 | |
| SCHEMBL24627649 | 0.80 | GGPS1 (0.57) | GGPS1ALOX15ALDH1A1 | |
| SCHEMBL14828668 | 0.77 | GGPS1 (0.32) | MAPK1GGPS1 | |
| SCHEMBL11123978 | 0.77 | BTN3A1 (0.32) | BTN3A1GGPS1ALOX15ALDH1A1 | |
| SCHEMBL11755129 | 0.75 | GGPS1 (0.31) | MAPK1GGPS1 | |
| SCHEMBL11755121 | 0.75 | GGPS1 (0.31) | MAPK1GGPS1 | |
| SCHEMBL9369217 | 0.75 | ALOX15 (0.42) | BTN3A1GGPS1ALOX15 | |
| SCHEMBL11141187 | 0.75 | GGPS1 (0.34) | BTN3A1GGPS1ALOX15ALDH1A1 | |
| SCHEMBL9796634 | 0.75 | BTN3A1 (0.31) | BTN3A1GGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109476640-A | Bicyclic proline compounds | 豪夫迈·罗氏有限公司 | 2019-03-15 | — | — | CN | disclosed |
| US-20180105749-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-04-19 | — | — | US | disclosed |
| US-20180057742-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-03-01 | — | — | US | disclosed |
| US-9868906-B2 | Liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2018-01-16 | — | — | US | disclosed |
| US-20180002605-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-04 | — | — | US | disclosed |
| US-9562190-B2 | Liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2017-02-07 | — | — | US | disclosed |
| US-20160168463-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2016-06-16 | — | — | US | disclosed |
| US-20160108314-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2016-04-21 | — | — | US | disclosed |
| US-9278989-B2 | Sugar-derived gelator | KYUSHU UNIVERSITY (JP) | 2016-03-08 | — | — | US | disclosed |
| US-9131719-B2 | Use of certain neoflavonoids for intensifying and/or producing a sensory impression of sweetness | SYMRISE AG (DE) | 2015-09-15 | — | — | US | disclosed |
| US-7705165-B2 | Method for producing optically active cyclopropanecarboxylate compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-27 | — | — | US | disclosed |
| US-7671210-B2 | Process for production of optically active cyclopropanecarboxylate compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-03-02 | — | — | US | disclosed |
| EP-1783130-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANECARBOXYLATE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2009-12-30 | — | — | EP | disclosed |
| US-20090048450-A1 | Process for production of optically active cyclopropanecarboxylate compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-02-19 | — | — | US | disclosed |
| US-20080027235-A1 | Method for Producing Optically Active Cyclopropanecarboxylate Compound | SUMITOMO CHEMICAL COMPANY, LIMITED | 2008-01-31 | — | — | US | disclosed |
| EP-1783111-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANECARBOXYLATE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2007-05-09 | — | — | EP | disclosed |
| EP-1783130-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANECARBOXYLATE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2007-05-09 | — | — | EP | disclosed |
| US-20070032659-A1 | Process for producing optically active cyclopropane compound and asymmetric copper complex for use in the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-02-08 | — | — | US | disclosed |
| CN-1852887-A | Process for producing optically active cyclopropane compound and asymmetric copper complex for use in the same | SUMITOMO CHEMICAL CO (JP) | 2006-10-25 | — | — | CN | disclosed |
| EP-1674445-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE CYCLOPROPANE COMPOUND AND ASYMMETRIC COPPER COMPLEX FOR USE IN THE SAME | Sumitomo Chemical Company, Limited (JP) | 2006-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027235-A1 | Method for Producing Optically Active Cyclopropanecarboxylate Compound | ACSL6, AOC1, CA6 | BTN3A1 1832/4885MAPK1 3759/4885GGPS1 2040/4885 |
| US-20090048450-A1 | Process for production of optically active cyclopropanecarboxylate compound | CBR3, C9, CBR1 | BTN3A1 295/4885MAPK1 3048/4885GGPS1 2986/4885 |
| US-20160168463-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | NLK, NCAPD2, LASP1 | BTN3A1 1409/4885MAPK1 2120/4885GGPS1 3398/4885 |
| US-20070032659-A1 | Process for producing optically active cyclopropane compound and asymmetric copper complex for use in the same | CBR3, AOC3, CBR1 | BTN3A1 2308/4885MAPK1 3205/4885GGPS1 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.